

University of Massachusetts Medical School

eScholarship@UMMS

PEER Liberia Project

UMass Medical School Collaborations in Liberia

2020-04-20

Opportunistic Infections, & Hepatitis B treatment & monitoring

Morgan Younkin

Lawrence Family Medicine Residency

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/liberia_peer



Part of the [Family Medicine Commons](#), [Health Services Administration Commons](#), [Infectious Disease Commons](#), [Medical Education Commons](#), and the [Virus Diseases Commons](#)

Repository Citation

Younkin M. (2020). Opportunistic Infections, & Hepatitis B treatment & monitoring. PEER Liberia Project. <https://doi.org/10.13028/yjrd-5a89>. Retrieved from https://escholarship.umassmed.edu/liberia_peer/73

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in PEER Liberia Project by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

Opportunistic Infections, & Hepatitis B treatment & monitoring

SESSION 3

HIV/HBV DIDACTIC SERIES

APRIL 20, 2020

MORGAN YOUNKIN, MD, MPH

FAMILY MEDICINE RESIDENT

LAWRENCE FAMILY MEDICINE RESIDENCY

LAWRENCE, MA, USA

Overall Outline

5 session, 2 hours each

1. HIV & ART overview
 - History, Epidemiology, transmission/risk, staging
 - Med Class Overview, ART initiation
2. Treatment monitoring & Failure
 - 2nd & 3rd line ART, toxicity/complications, monitoring
 - Prevention
3. Opportunistic Infections & Hepatitis B
 - OIs, ART considerations, Prophylaxis
 - HBV dx, tx, surveillance, & HIV-HBV co-infection
4. Special Populations:
 - Pregnancy, antenatal & intrapartum, infant care & pediatric
5. HIV/HBV Case-Based Application
 1. Case Application
 2. Wrap-up/review, miscellaneous items

Source Materials

Liberia Integrated Guidelines for Prevention, Testing, Care, and Treatment of HIV and AIDS

- 5th edition, August 2019

WHO HIV Diagnosis, Treatment, and Opportunistic Infection Guidelines

- 2016, 2018 ART update
- https://www.who.int/publications/guidelines/hiv_aids/en/

WHO Hepatitis B treatment guidelines (2015)

- <https://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/>

ELWA Hepatitis B Treatment Protocol.

Zambia National Hepatitis B Treatment Protocol.

Reference Materials

Department of Health & Human Services. HIV Guidelines. USA. <https://aidsinfo.nih.gov/guidelines>

Fundamentals of HIV Medicine. American Academy of HIV Medicine. Oxford University Press. 2017 Edition.

National HIV Curriculum. University of Washington & CDC. USA. <https://www.hiv.uw.edu/>

AIDS-defining conditions

Recurrent bacterial infections

Candidiasis “below” the mouth

Invasive cervical cancer

Coccidioidomycosis

Cryptococcosis

Cryptosporidiosis

Cytomegalovirus

Chronic HSV

Disseminated Histoplasmosis

Kaposi Sarcoma

Mycobacterium Avium Complex (MAC)

Mycobacterium Tuberculosis

Pneumocystis Jirovecii Pneumonia

Progressive Multifocal Leukoencephalopathy

Toxoplasmosis gondii of brain

HIV wasting syndrome

HIV encephalopathy

Cystoisosporiasis (Isosporiasis), chronic

Lymphoma (Burkitt, Primary CNS, or immunoblastic)

Non-AIDS-defining Conditions

Bacterial Enteric Infections

Hepatitis B

Oropharyngeal Candidiasis

Hepatitis C

Community-Acquired Pneumonia

Bartonella

Leishmaniasis

Malaria

Latent MTB

Syphilis

Varicella-Zoster

Talaromycosis

Oral & Cutaneous Conditions

Oropharyngeal Candidiasis

Oral Hairy Leukoplakia

HSV

Anogenital Warts

Scabies

Molluscum Contagiosum

Eosinophilic Folliculitis

Bacillary Angiomatosis

Seborrheic Dermatitis

Mycobacterium
Reactivation OR primary disease

Mycobacterium Tuberculosis

Epidemiology:


PLHV: 10% annual & 50%
lifetime risk
Most common cause of death

Presentation:

Variable & atypical sx!
Anemia, fever, weight loss

Diagnosis:

Think pre-test probability!
Xpert; smear (but most are negative); culture
If CD4 <200 -> routinely screen urine LAM
- if + => give TBT; does not r/o dz if neg



Management:

Don't delay; if sick > empiric!

ART considerations:

CD4 <50 = ART within 2 weeks

CD4 >50 = ART at 8 weeks

TB meningitis = generally defer ART until 8 weeks

Avoid: NVP, ATV/r, LPV/r, DRV/r

DTG: *best option*, but double dose of DTG for rifampicin

TB Preventive Therapy (TPT):

All HIV+, start w/ ART either:

- 6H (INH x6mo)
- 3HP (RFP/INH wkly x12)

Fungus
Reactivation OR Primary disease

Cryptococcosis

Epidemiology:

CD4 <100-200

Presentation:

Indolent, headache, AMS, +/-
fever, rash similar to molluscum

Diagnosis:

CrAg (serum (95%+) or CSF)
India Ink stain, ^opening pressure
If CD4 <200 = routinely screen with
serum CrAg

Management:

Induction Phase


Option 1: AmphoB/flucytosine x7d
Option 2: Fluconazole/flucytosine x14d
Option 3: AmphoB/fluconazole x14d

Consolidation Phase

Fluconazole 800mg daily

Maintenance phase

Fluconazole 200mg daily for life



ART considerations:

Start ART only 5 weeks *after*
antifungal tx initiation

Prevention:

None (other than ART)

Parasite
Reactivation of latent infection

Toxoplasmosis Gondii

Epidemiology:

CD4 <100

Results from reactivation of previously latent dz

Presentation:

New CNS alteration

Retinitis, pneumonitis, disseminated


Diagnosis:

Presumptive clinical diagnosis

CT with ring enhancing lesions

CSF studies (PCR specific, not sensitive)

IgG negative = excellent NPV



Management:

Cotrim 960mg:

4 tab BID x6wk, then

2 tab BID x3mo, then

1 tab BID lifelong

ART considerations:

Start ART within 2-3 weeks

Prevention:

If CD4 <100 give cotrim ppx

Pneumocystis Jiroveci (carinii) Pneumonia (PJP)

Fungus
Likely re-infection

Epidemiology:

CD4 <200 predominates

Presentation:

Subacute, nonproductive cough,
fever, hypoxia, often no rales
Infant: severe PNA

Diagnosis:

Ambulatory hypoxia

CXR

CSF studies (PCR specific, not sensitive)

IgG negative = excellent NPV



Management:

Cotrim x21d

If hypoxic give prednisolone
x21d (start with cotrim)

ART considerations:

Start ART within 2 weeks

Prevention:
CPT lifelong

non-TB mycobacterium group
Ubiquitous in environment

Mycobacterium Avium Complex

Epidemiology:

CD4 <50
ART decreases population prevalence

Presentation:

Nonspecific/indolent – fever, fatigue, diarrhea, weight loss, abd pain, diffuse LAD

Diagnosis:

Presumptive clinical diagnosis
Blood Culture x2 (90% sensitive by 14d growth)

Management:


Macrolide & ethambutol
x12mo

ART considerations:

Start ART immediately

Prevention:

ART



ds-DNA herpes virus
Reactivation of latent infection

Cytomegalovirus

Epidemiology:

CD4 <50

Risk factors: MSM, high HIV RNA,
prior OI

Presentation: indolent

Retinitis – floaters, flashes, field deficits, failing
vision, often unilateral
CNS (encephalitis), GI (diarrhea, weight loss,
esophagitis)

Diagnosis: clinical

Retinal exam, endoscopy (mucosal
ulcerations, biopsy), CSF PCR

Management:


IV ganciclovir or intravitreal
injxn

ART considerations:

Start ART 2wks after tx start
Significant IRIS risk

Prevention:

ART



fungus

Reactivation of latent infection

Histoplasmosis

Epidemiology:


Endemic in most tropical regions
CD4 <150

Presentation: *many* variations

Disseminated: fever, wt loss, cough
Encephalitis, GI, hepatomegaly

Diagnosis:

CXR: nodules, diffuse patchy opacities
Urine Ag



Management:

Severe: amphotericin B > itraconazole x12mo
Non-severe: itraconazole x12mo

ART considerations:

Start ART immediately

Prevention:

2* ppx stopped after 1yr when on ART with undetectable RNA & Histoplasma Ag not detected

Cryptosporidiosis

Epidemiology:

Contaminated water (persists despite chlorination), person-to-person

Presentation:

watery diarrhea, vomiting
Chronic OR profuse

Diagnosis:

Stool ova & parasite with modified acid-fast stain

Management:


Immediate ART
Supportive treatment

ART considerations:

Start ART immediately

Prevention:

ART



Microsporidiosis

Epidemiology:


Untreated drinking water
CD4 <100

Presentation:

diarrhea

Diagnosis:

Clinical diagnosis
Stool microscopy



Management:

ART (sx stop when CD4 >100)
Some species: albendazole,
itraconazole

ART considerations:

Start ART immediately

Prevention:

ART

Isosporidiosis (“cystoisosporiasis”)

Epidemiology:


Tropical regions
Fecal-oral route
CD4 <250

Presentation:

Watery diarrhea, vomiting, low grade fever

Diagnosis:

Presumptive clinical diagnosis
Large oocysts on modified acid-fast stool microscopy



Management:

Cotrim TID for 10-30d

ART considerations:

Start ART immediately

Prevention:

CPT with ART

Candidiasis

Epidemiology:

CD4 < 100-200

Presentation:

Oral: white/red patches
 Esophageal: odynophagia
 Vaginal: vaginitis, discharge

Diagnosis:

Presumptive clinical diagnosis
 Wet prep if vaginal

Management:


Oral: nystatin topical x7-14d
 Esophageal: fluconazole x14d
 Vaginal: topical or oral x1

ART considerations:

Start ART immediately

Prevention:

ART



Virus
Reactivation of latent

Herpes Zoster (shingles)

Epidemiology:

CD4 <200
15x risk in HIV+ compared to
HIV neg

Presentation:

Dermatomal distribution
Caution trigeminal nerve involvement

Diagnosis:

Presumptive clinical diagnosis

Management:

Acyclovir x7d within 72hrs of
symptom start
Ophtho for CN V
Pain control

ART considerations:

Start ART immediately

Prevention:

vaccination



Scabies

Epidemiology:
Skin-to-skin contact
Crusted (Norwegian) scabies =
airborne

Presentation:
Pruritis; papules & thin short “burrows”
Crusted: severe, widespread, crusted

Diagnosis:
Presumptive clinical diagnosis



Management:
Topical permethrin
Oral ivermectin
tx contacts
Crusted: ivermectin

ART considerations:
Start ART

Vascular tumor caused by human herpes virus-8 (HHV-8)

Kaposi Sarcoma (KS)

Epidemiology:

CD4 <150

Presentation:



Purple/red/brown patch > plaque > nodule

Cutaneous, mucous membrane, visceral organ (GI, pulm, lymphatic)

Pediatric: woody inguinal oedema

Diagnosis:

Presumptive clinical diagnosis
biopsy



Management:

KS Stage T0 (adults with only cutaneous KS) = ART x3mo

KS Stage T1 (any pediatric & adult w/ oedema, nodules, non-cutaneous involvement):

- paclitaxel chemo
- bleomycin/vincristine

ART considerations:

Start ART

Prevention:

ART

Lymphoma

Epidemiology:

Burkitt
Primary CNS

Presentation:

LAD, weight loss, fever, anemia
CNS findings

Diagnosis:

Biopsy
Consider if failure to improve after TB
treatment x4wks in suspicious cases



Management:

Oncology

ART considerations:

Start ART

Prevention:

ART

Progressive Multifocal Leukoencephalopathy

JC virus
reactivation

Epidemiology:


80% JC worldwide seroprevalence
Immunocompromise > reactivation

Presentation:

subacute CNS alteration
20% seizure
Fever & acute encephalopathy rare

Diagnosis:

Presumptive clinical diagnosis
MRI



Management:

ART

ART considerations:

Start ART immediately

Prevention:

ART

IRIS (Immune Reconstitution Inflammatory Syndrome)

Disease- or pathogen-specific inflammatory state that may occur after initiation of ART

- **Paradoxical:** worsening of previously diagnosed disease
- **Unmasking:** appearance of previously undiagnosed disease

Rules of thumb:

- Treat the IRIS-specific condition as indicated
- Continue ART

TB-IRIS

- Give steroids (4 weeks)